Yuyu Pharma Invests in Dalan Animal Health to Expand Global Footprint

Yuyu Pharma has completed a strategic investment in Dalan Animal Health, a U.S.-based biotechnology firm known for its innovative vaccine development. This investment, announced on December 2, 2025, aims to boost Yuyu Pharma’s presence in the rapidly growing animal health sector, which has gained significant attention in recent years.

Dalan Animal Health is recognized for creating the world’s first USDA-approved honeybee vaccine and is currently working on a pioneering shrimp vaccine. This initiative is expected to transform disease management practices in global aquaculture, an area of increasing importance due to the rising demand for sustainable food resources. With this investment, Dalan plans to expand its platform to include other species, particularly poultry and various aquaculture species, where their technology could facilitate broad-spectrum disease prevention and reduce reliance on antibiotics.

In a statement, Robert Wonsang Yu, Chief Executive Officer of Yuyu Pharma, emphasized the strategic significance of this investment. “Yuyu Pharma is moving decisively into new areas of animal health where scientific innovation can create lasting global impact,” he said. He highlighted the essential roles that bees, shrimp, and other species play in food systems and environmental stability, further underscoring the importance of investing in technologies that will shape the future of animal health.

Expanding into Companion Animal Health

Yuyu Pharma is also broadening its focus within the companion animal health sector. Recent investments in companies such as VetmAb Bio—developer of species-specific monoclonal antibodies for dogs and cats—and DogPPL, a premium community and wellness platform for pet owners in the United States, reflect a commitment to understanding evolving consumer expectations and advancements in the pet care industry.

“Animal health is becoming a global growth engine, driven by advances in biologics, sustainable aquaculture, and rising demand for high-quality companion animal care,” Mr. Yu noted. This proactive approach positions Yuyu Pharma not merely as an observer but as an active contributor in the dynamic landscape of animal health technologies.

Through these strategic investments, Yuyu Pharma is building a diversified and globally-oriented portfolio that encompasses veterinary biologics, sustainable food-system technologies, and innovative pet wellness models. This multi-faceted strategy aims to ensure that the company remains at the forefront of advancements in animal health, aligning with broader global health and agricultural priorities.

About Yuyu Pharma

Founded in 1941, Yuyu Pharma is a South Korea-based healthcare company dedicated to advancing medicines, medical devices, and health solutions that enhance quality of life. As part of its comprehensive global expansion strategy, the company actively invests in early-stage and high-growth innovators across various sectors, including biotechnology, sustainability, and animal health. This latest investment in Dalan Animal Health underscores Yuyu Pharma’s commitment to playing a pivotal role in the future of animal health and food sustainability.